Randomized Phase II Study of Sorafenib With or Without Everolimus in Patients With Radioactive Iodine Refractory Hurthle Cell Thyroid Cancer
Status: Active, no longer recruiting
Phase of Trial: Phase II
Latest Information Update: 20 Sep 2019
Price : $35 *
At a glance
- Drugs Everolimus (Primary) ; Sorafenib
- Indications Thyroid cancer
- Focus Therapeutic Use
- 18 Sep 2019 Status changed from recruiting to active, no longer recruiting.
- 16 Nov 2016 Planned number of patients changed from 56 to 34.
- 24 Sep 2015 Planned primary completion date changed from 1 Jul 2020 to 1 Aug 2020 as reported by ClinicalTrials.gov record.